<DOC>
	<DOCNO>NCT02174276</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , efficacy GS-4774 adult chronic hepatitis B infection ( CHB ) currently treatment . Participants randomize receive tenofovir disoproxil fumarate ( TDF ) alone GS-4774 plus TDF 20 week . After Week 20 , GS-4774 discontinue . All participant continue TDF follow additional 28 week . Following completion 48 week study period , participant eligible 3 year registry study .</brief_summary>
	<brief_title>Safety Efficacy GS-4774 Combination With Tenofovir Disoproxil Fumarate ( TDF ) Treatment Subjects With Chronic Hepatitis B Who Are Currently Not Treatment</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Key Must ability understand sign write informed consent form , must obtain prior initiation study Documented evidence chronic HBV infection ( e.g. , HBsAg positive 6 month ) Screening HBV DNA â‰¥ 2000 IU/mL A negative serum pregnancy test require female subject ( unless surgically sterile great two year postmenopausal ) Key Cirrhosis Inadequate liver function Coinfection hepatitis C virus ( HCV ) , HIV hepatitis D virus ( HDV ) Received antiviral treatment HBV within 3 month screen Evidence hepatocellular carcinoma ( e.g. , evidenced recent imaging ) Significant cardiovascular , pulmonary , neurological disease Women pregnant may wish become pregnant course study Received solid organ bone marrow transplant Received prolonged therapy immunomodulators ( e.g. , corticosteroid ) biologics ( e.g. , monoclonal Ab , interferon ) within 3 month screen Use investigational agent within 3 month screen Current alcohol substance abuse judge investigator potentially interfere subject compliance Receipt immunoglobulin blood product within 3 month prior enrollment History demyelinate disease ( GuillainBarre ) , Bell 's Palsy , Crohn 's disease , Ulcerative colitis , autoimmune disease Documented history yeast allergy Known hypersensitivity study drug , metabolite formulation excipients Malignancy within 5 year prior screen , exception specific cancer cure surgical resection ( basal cell skin cancer , etc ) . Subjects evaluation possible malignancy eligible Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>